The 13.2 mg dose is equivalent to 188 μg/kg eflapegrastim (51 μg/kg G‐CSF) for a 70 kg person and was chosen based on the results of a Phase 2 dose‐ranging study, which showed noninferiority of eflapegrastim vs pegfilgrastim in the primary endpoint, mean Cycle 1 duration of severe neutropenia (DSN), for eflapegrastim 135 μg/kg (37 μg/kg G‐CSF) (0.44 vs. 0.31 days, P = .002), and statistical superiority at 270 μg/kg (74 μg/kg G‐CSF) (0.03 vs. 0.31 days, P = .023).7 This evidence concerns the gene CSF3 and Decreased total neutrophil count.